Sermorelin vs CJC-1295: Comparing Two GH Secretagogues

Sermorelin and CJC-1295 are often discussed in the same breath, and for good reason: both are growth-hormone-releasing hormone (GHRH) analogues that prompt the pituitary to release its own growth hormone (GH) rather than introducing GH directly. That shared mechanism is where the easy similarities end. The practical differences — how long they last, how they’re dosed, and how much human evidence stands behind each — matter more than the marketing usually admits.

The mechanism they share

Both compounds bind GHRH receptors on the pituitary and stimulate a pulse of endogenous GH. In principle this is a gentler approach than injecting recombinant GH, because the body’s own feedback loops still have a say. That theoretical advantage is appealing, but “more physiological” is a mechanistic argument, not a demonstrated clinical outcome in healthy adults.

Stimulating your own GH release is biologically plausible — and not the same as proving meaningful, durable benefits in healthy people. The peer-reviewed human outcome literature here is thin.

Where they diverge

The headline difference is half-life.

	Half-life	Dosing	Human data
Sermorelin (GHRH 1-29)	~4 minutes in plasma	Frequent	Oldest regulatory history — held FDA approval for pediatric GH deficiency, commercially withdrawn in 2008
CJC-1295 without DAC	Not reported in any human study	Frequent	No peer-reviewed human pharmacokinetic data
CJC-1295 with DAC	5.8–8.1 days	Weekly/biweekly	One PK/PD study; no outcome trials in healthy adults

Sermorelin’s number is the one people usually get wrong. When GHRH-(1-29)-NH2 was infused intravenously into ten normal men, its disappearance half-time was 4.3 ± 1.4 minutes — the peptide is cleared in minutes, not tens of minutes. (The GH response to a subcutaneous dose outlasts the peptide itself; the two are different measurements and are often conflated.) The half-life for CJC-1295 without DAC is not a small number — it is an absent one: a 2026 review in Frontiers in Endocrinology that catalogued the peer-reviewed evidence for each of these compounds records no human study reporting it at all.

The “with DAC” version is the source of most confusion. The Drug Affinity Complex is a maleimide group that bonds the peptide to the free thiol on Cys34 of serum albumin, so the peptide circulates attached to a protein the body clears slowly. That mechanism was worked out at ConjuChem in rats and with human albumin ex vivo, in the 2005 Endocrinology paper that named CJC-1295 as the best of three candidates. The human figures come from Teichman et al. (2006) in The Journal of Clinical Endocrinology & Metabolism — two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21–61, which found a single CJC-1295 injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days, with an estimated half-life of 5.8–8.1 days.

Why the duration matters

Pulsatile GH release is how healthy physiology works. A continuous, days-long elevation may not replicate the same downstream signaling — and that PK study measured hormone levels, not health outcomes. Whether the longer-acting version is better, worse, or simply different is not settled by the data we have.

What the evidence actually supports

Sermorelin has the deepest paper trail, including a period holding FDA approval for pediatric growth hormone deficiency before it was withdrawn from the market in 2008. CJC-1295’s published human data is essentially a single pharmacokinetic study; claims about fat loss, recovery, or anti-aging in healthy adults run well ahead of what’s been demonstrated. Neither compound holds any current regulatory approval for a performance or body-composition indication. Both share the realities of the category: outside approved indications, supply is unregulated, purity varies, and long-term safety in healthy people hasn’t been characterized.

The takeaway

They share a mechanism but differ in duration: sermorelin has more history, while CJC-1295’s DAC form is more theoretically aggressive and studied mainly for its hormone-elevating pharmacokinetics, not for clinical benefit. None of that adds up to a confident recommendation. The biology is interesting; the human evidence for benefit in healthy adults is not yet there.

Sources

• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
• Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–8.
• Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994;79(4):1208–11.
• Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026;17:1822475.